TOP-5 Price Targets by Analysts on December 9, 2025
Reading Time: 3 minutes
Viatris Inc. [US92556V1061] Barclays initiates coverage with " Overweight " and a price target of 15 USD (35% upside potential) In his analysis, Barclays analyst Glen Santangelo emphasizes that investor sentiment across the specialty pharma sector is improving. Reasons for this include a greater focus of companies on innovation, margin improvement, and debt reduction. Additionally, pricing pressure in the specialty pharma sector is easing, while overall debt is decreasing. Therefore, Barclays sees " significant potential,” as the sector...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
